Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
uniQure (QURE) has provided an update.
uniQure N.V. has released promising interim results from its Phase I/II clinical trials of AMT-130, a gene therapy aimed at treating Huntington’s disease. Data from patients in both U.S. and European trials show a significant slowing in disease progression, particularly in those receiving a high dose of the therapy. Additionally, there was a notable reduction in neurofilament light chain levels, an important biomarker of neurodegeneration. AMT-130 has maintained a good safety profile with no serious adverse events related to the treatment reported. These encouraging findings suggest potential for AMT-130 to change the management of Huntington’s disease.
See more insights into QURE stock on TipRanks’ Stock Analysis page.